CosmosID detects and identifies microorganisms of all kinds – bacteria, viruses, fungi and protists – using next-generation sequencing. Thanks to this method, pharmaceutical and nutraceutical companies can carry out R&D on the human microbiome.

We discussed CosmosID’s approach with Arne Materna, the company’s Vice President Product, during the fourth edition of Microbiome Movement Drug Development Europe held in London.